Exhibit 10.88


 


SUBSCRIPTION AGREEMENT


 


This
SUBSCRIPTION Agreement (this “Agreement”) is made as of July 3, 2014 by, and between CNS Response,
Inc., a Delaware corporation (the “Company”), and the investor(s) listed on Schedule A hereto (each,
an “Investor,” and collectively, the “Investors”).


 


WITNESSETH


 


In consideration for
the mutual promises and covenants herein, the parties agree as follows:


 


WHEREAS, the
Company is offering, in a private placement, up to $1.0 million of its Common Stock (“Common Stock”), par value
$0.001 per share (the “Shares”) for $0.25 per share in a private placement to accredited investors pursuant
to a Confidential Offering Memorandum dated July 3, 2014; and


 


WHEREAS, the
undersigned desires to subscribe for and purchase the number of Shares set forth on Schedule A hereto.


 


Section
1 – Purchase and Sale of SHARES


 


1.1          Purchase
and Sale of Shares. The Company has authorized the issuance and sale, in accordance with the terms hereof, of shares of Common
Stock, in the aggregate amount of up to $1,000,000 (the “Shares Cap Amount”),
subject to increase at the discretion of the Board of Directors of the Company (the “Board”).
On the terms and subject to the conditions set forth in this Agreement, at the Closings (as defined below), the Company agrees
to issue to each Investor, and the Investor agrees to purchase from the Company, in the amount set forth on Schedule A.
The Company will sell Shares to more than one Investor, each of whom will enter into Subscription Agreement substantially identical
to this one. 


 


1.2          Closings.



 


(a)          Initial
Closing. The initial purchase and sale of the Shares shall take place at a closing (the “Initial Closing”)
which shall take place remotely via exchange of documents and signatures at 10:00 a.m. Eastern Time on the business day immediately
following execution and delivery of this Agreement, or at such other place and time as may be agreed to among the Company and the
Investors. At the Initial Closing, the Company shall deliver to each of the Investors purchasing Shares for cash at such initial
closing a certificate or certification representing such number of Shares as is set forth opposite such Investor’s name on
Schedule A hereto against receipt of a check subject to collection or a wire transfer in immediately available funds of
the purchase price, to an account designated by the Company. 


 




    	 



    	 



    

  


(b)          Additional
Closings. The Company shall have the right, on one or more occasions, to hold additional closings (each, an “Additional
Closing,” and, collectively with the Initial Closing, the “Closings,”
and individually, a “Closing”), pursuant to which it shall have the right
to issue and sell additional Shares to additional Investors or existing Investors (provided that no Additional Closings shall take
place later than July 31, 2014, unless extended by the Board or upon the withdrawal of this offering by the Board, whichever occurs
sooner). At each Additional Closing, the Company shall deliver to each Investor purchasing Shares at such additional closing a
certificate or certification representing such number of Shares as is set forth opposite such Investor’s name on Schedule
A hereto against receipt of a check subject to collection or a wire transfer in immediately available funds of the purchase
price, to an account designated by the Company. By receiving Shares at an Additional Closing, each Investor so receiving Shares
thereby represents that its representations and warranties contained in Section 3 are true and correct as of the date of such Additional
Closing. The aggregate principal amount of Shares that may be issued at Closings hereunder shall, in no event exceed the Board
approved Share Cap Amount.


 


The obligation of each
Investor to purchase and pay cash for the Shares to be delivered at a Closing is, unless waived by such Investor, subject to the
condition that the Company’s representations and warranties contained in Section 2 are true, complete and correct on and
as of such Closing date. The obligation of the Company to sell and issue Shares to be delivered at a Closing is, unless waived
by the Company, subject to the condition that the relevant Investor’s representations and warranties contained in Section
3 are true, complete and correct on and as of the Closing Date.


 


Section
2 - Representations and Warranties


of
the Company


 


The Company represents
and warrants to each Investor as follows:


 


2.1         Existence
of Company. The Company is a duly organized Delaware corporation. The Company is validly existing in all jurisdictions where
it conducts its business.


 


2.2          Authority
to Execute. The execution, delivery and performance by the Company of this Agreement and the issuance of the Shares are within
the Company’s corporate powers, have been duly authorized by all necessary corporate action, do not and will not conflict
with any provision of law or organizational document of the Company (including its Certificate of Incorporation or Bylaws) or of
any agreement or contractual restrictions binding upon or affecting the Company or any of its property and need no further stockholder
or creditor consent.


 


2.3         No
Stockholder Approval Required. No approval of the Company’s stockholders is required for (i) the entry by the Company
into this Agreement, or (ii) the issuance of the Shares contemplated by this Agreement.


 


2.4         Valid
Issuance. The Shares will be, validly issued, fully paid and nonassessable and free of restrictions on transfer other than
restrictions on transfer under, applicable state and federal securities laws and liens or encumbrances created by or imposed by
the Investor. Assuming the accuracy of the representations of the Investor in Section 3 of this Agreement, and the Shares will
be issued in compliance with all applicable federal and state securities laws.


 




    	 



    	 



    

  


2.5         Binding
Obligation. This Agreement is, a valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar
laws affecting creditors’ rights generally and to general equitable principles.


 


2.6         Litigation.
Other than the litigation disclosed in the Company’s most recent SEC Reports (as defined below), no litigation or governmental
proceeding is pending or threatened against the Company which may have a materially adverse effect on the financial condition,
operations or prospects of the Company, and to the knowledge of the Company, no basis therefore exists.


 


2.7         Intellectual
Property. To the best of the Company’s knowledge, the Company owns or possesses sufficient legal rights to all patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes
necessary for its business as now conducted and as presently proposed to be conducted, without any known infringement of the rights
of others. There are no outstanding options, licenses or agreements of any kind relating to the foregoing proprietary rights, nor
is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks,
service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any
other person or entity other than such licenses or agreements arising from the purchase of “off the shelf” or standard
products.


 


2.8         SEC
Reports. The Company has filed all forms, reports, schedules, proxy statements,
registration statements and other documents (including all exhibits thereto) required to be filed by it with the U.S Securities
and Exchange Commission (the “SEC”) pursuant to the federal securities laws and the SEC rules and regulations
thereunder, together with all certifications required pursuant to the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley
Act”) (as they have been amended since the time of their filing, including all exhibits thereto, the “SEC Reports”).
Each of the SEC Reports complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended
(the “Securities Act”) and the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act and the rules
and regulations of the SEC under all of the foregoing. None of the SEC Reports contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading.


 


Section
3 - Representations and Warranties


of
the Investors


 


Each Investor represents
and warrants to the Company as follows:


 


3.1         Authorization;
Binding Obligations. The Investor has full power and authority to enter into this Agreement and this Agreement constitutes
a valid and legally binding obligation of the Investor, enforceable against the Investor in accordance with its terms, subject,
as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’
rights generally and to general equitable principles.


 




    	 



    	 



    

  


3.2         Accredited
Investor. The Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D promulgated
under the Securities Act.


 


3.3         Investment
for Own Account. The Shares are being acquired for his, her or its own account, for investment and not with a view to, or for
resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act.


 


3.4         Knowledge
and Experience. The Investor has such knowledge and experience in financial and business matters that (s)he is capable of evaluating
the merits and risks of an investment in the Shares and of making an informed investment decision with respect thereto, has the
ability and capacity to protect his/her interests and can bear the economic risk of the acceptance of the Shares, including a total
loss of his/her investment.


 


3.5        Opportunity
to Ask Questions. The Investor has had the opportunity to ask questions and receive answers from the Company or any authorized
person acting on its behalf concerning the Company and its business and to obtain any additional information, to the extent possessed
by the Company (or to the extent it could have been acquired by the Company without unreasonable effort or expense) necessary to
verify the accuracy of the information received by the Investor. In connection therewith, the Investor acknowledges that (s)he
has had the opportunity to discuss the Company’s business, management and financial affairs with the Company’s management
or any authorized person acting on its behalf.


 


3.6.        Receipt
of Information. The Investor has received and reviewed all of the information concerning the Company and the Shares, both written
and oral, that the Investor desires. Without limiting the generality of the foregoing, the Investor has been furnished with or
has had the opportunity to acquire, and to review: all information, both written and oral, that the Investor desires with respect
to the Company’s business, management, financial affairs and prospects. In determining whether to make this investment, the
Investor has relied solely on his/her own knowledge and understanding of the Company and its business and prospects based upon
the Investor’s own due diligence investigations and the Company’s filings with the SEC.


 


Section
4 - Miscellaneous


 


4.1          No
Waiver; Cumulative Remedies. No failure or delay on the part of any party to this Agreement in exercising any right or remedy
under, or pursuant to, this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such right,
remedy or power preclude other or further exercise thereof, or the exercise of any other right, remedy or power. The remedies in
this Agreement are cumulative and are not exclusive of any remedies provided by law.


 


4.2          Amendments
and Waivers. Except as otherwise expressly set forth in this Agreement, any term of this Agreement may be amended (either retroactively
or prospectively) with the written consent of the Company and the Investor. Any amendment effected in accordance with this Section
4.2 shall be binding upon each Investor, each future holder of Shares and the Company.


 




    	 



    	 



    

  


4.3          Notices,
Etc. All notices, requests, consents and other communications hereunder to any party shall be deemed to be sufficient if contained
in a written instrument delivered in person; sent by facsimile transmission; sent by electronic mail; duly sent by first class
registered or certified mail, return receipt requested, postage prepaid; or duly sent by overnight delivery service (e.g.,
Federal Express) addressed to such party (i) if to the Company, at the address, fax number or electronic mail address, as applicable,
set forth on the signature page hereof or (ii) if to an Investor, at the address, fax number or electronic mail address, as applicable,
set forth on Schedule A hereto, or at such other address, fax number or electronic mail address as may hereafter be designated
in writing by the addressee to the sender. All such notices, advises and communications shall be deemed to have been received:
(a) in the case of personal delivery, on the date of such delivery; (b) in the case of facsimile or electronic mail transmission,
on the date of transmission; and (c) in the case of mailing or delivery by service, on the date of delivery as shown on the return
receipt or delivery service statement.


 


4.4          Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard
to the conflicts of law provisions of the State of California or of any other state. The Company and each Investor consent to personal
jurisdiction in Orange County, California.


 


4.5          Severability.
If any term in this Agreement is held to be illegal or unenforceable, the remaining portions of this Agreement shall not be affected,
and this Agreement shall be construed and enforced as if this Agreement did not contain the term held to be illegal or unenforceable.


 


4.6          Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the Company and each Investor and their respective
successors and assigns.


 


4.7          Transfer
of Shares. Notwithstanding the legend required to be placed on the Shares by applicable law, no registration statement or opinion
of counsel shall be necessary: (a) for a transfer of Shares to the respective estate of each Investor or for a transfer of Shares
by gift, will or intestate succession of each Investor to his or her spouse or to the siblings, lineal descendants or ancestors
each Investor or his or her spouse, if the transferee agrees in writing to be subject to the terms hereof to the same extent as
if he or she were the original Investor hereunder; or (b) for a transfer of Shares pursuant to SEC Rule 144 or any successor rule,
or for a transfer of Shares pursuant to a registration statement declared effective by the SEC under the Securities Act relating
to the Shares.


 


4.8          Survival
of Representations, Warranties and Covenants. The representations and warranties of the parties contained in or made pursuant
to this Agreement shall survive the execution and delivery of this Agreement indefinitely, and shall in no way be affected by any
investigation of the subject matter thereof made by or on behalf of the other parties. The covenants of the parties contained in
or made pursuant to this Agreement shall survive the execution and delivery of this Agreement until such time as the Notes have
been paid in full.


 




    	 



    	 



    

  


4.9          California
Commissioner of Corporations. THE SALE OF THE SHARES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SHARES OR PAYMENT OR RECEIPT OF ANY PART OF THE
CONSIDERATION FOR SUCH SHARES PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SHARES IS EXEMPT FROM QUALIFICATIONS BY
SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED
UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.


 


[Remainder of Page Intentionally Left
Blank]


 




    	 



    	 



    

  


IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as
of the date first written above.


 


	 	CNS RESPONSE, INC.
	 	 
	 	By:	 
	 	 	Name: Paul Buck
	 	 	Title: Chief Financial Officer


 


Address/Fax Number/E-mail Address for Notice:


 


85 Enterprise, Suite 410


Aliso Viejo, CA 92656


Fax: (866) 867 4446


pbuck@cnsresponse.com


 


	 	INVESTOR:
	 	 
	 	By:	 
	 	 	Name:
	 	 	 
	 	 	Title: 


 




    	 



    	 



    

  


SCHEDULE A


 


	Name,
    Address, Fax Number, E-Mail Address and Tax ID Number of Investor 	 	Aggregate
Purchase Price 

	
         

         

        Name:_________________________________

         

        Address:_______________________________

         

        ______________________________________

         

        Fax:__________________________________

         

        Email:_________________________________

         

        Tax ID:________________________________

         
	 	
         

         

        $______________________

	TOTAL: